MX2016009226A - Combinaciones farmaceuticas. - Google Patents

Combinaciones farmaceuticas.

Info

Publication number
MX2016009226A
MX2016009226A MX2016009226A MX2016009226A MX2016009226A MX 2016009226 A MX2016009226 A MX 2016009226A MX 2016009226 A MX2016009226 A MX 2016009226A MX 2016009226 A MX2016009226 A MX 2016009226A MX 2016009226 A MX2016009226 A MX 2016009226A
Authority
MX
Mexico
Prior art keywords
combination
cancer
amide
prevention
subject
Prior art date
Application number
MX2016009226A
Other languages
English (en)
Inventor
Hirawat Samit
Massacesi Cristian
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2016009226A publication Critical patent/MX2016009226A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una combinación farmacéutica que comprende: (a) un inhibidor de la fosfatidilinositol-3-quinasa seleccionado entre 5- (2,6-di-morfolin-4-iI-pirimidin-4-il)-4-trifluorometil-piridin-2- ilamina, 2-amida 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-eti l)-piridin-4-il] tiazol-2 il}-amida) del ácido (S)-pirrolidin 1,2-dicarboxílico o cualquier sal farmacéuticamente aceptable del mismo y (b) un agonista de gonadorelina y, opcionalmente, (c) un agente antiestrógeno, en particular para uso en el tratamiento o la prevención de un cáncer; usos de tal combinación en la preparación de un medicamento para el tratamiento o la prevención de un cáncer; composiciones farmacéuticas de la combinación de dichos agentes terapéuticos y métodos de tratamiento de un cáncer en un sujeto, que comprende administrar a dicho sujeto una cantidad terapéuticamente eficaz de una combinación de este tipo.
MX2016009226A 2014-01-15 2015-01-13 Combinaciones farmaceuticas. MX2016009226A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14305057 2014-01-15
PCT/IB2015/050260 WO2015107461A1 (en) 2014-01-15 2015-01-13 Pharmaceutical combinations

Publications (1)

Publication Number Publication Date
MX2016009226A true MX2016009226A (es) 2016-10-05

Family

ID=50033443

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016009226A MX2016009226A (es) 2014-01-15 2015-01-13 Combinaciones farmaceuticas.

Country Status (11)

Country Link
US (2) US20160331755A1 (es)
EP (1) EP3094340A1 (es)
JP (2) JP2017502989A (es)
KR (1) KR20160101027A (es)
CN (2) CN112535688A (es)
AU (2) AU2015207723A1 (es)
BR (1) BR112016012141A2 (es)
CA (1) CA2936783A1 (es)
MX (1) MX2016009226A (es)
RU (2) RU2020121929A (es)
WO (1) WO2015107461A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111757734A (zh) * 2017-12-28 2020-10-09 星座制药公司 通过组合疗法的ezh2抑制剂的药代动力学增强
WO2023150267A1 (en) * 2022-02-03 2023-08-10 Maison Amori Oqvpo Llc Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
JP2008528469A (ja) * 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
CN101019828A (zh) * 2007-03-23 2007-08-22 济南帅华医药科技有限公司 一种含磷酸肌醇3－激酶抑制剂及激素类药物的抗癌组合物
MX2009012066A (es) * 2007-05-09 2009-11-19 Novartis Ag Imidazopirinas sustituidas como inhibidoras de cinasa de lipido p13k.
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EP2558463A1 (en) * 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
PT2592933T (pt) * 2010-07-16 2017-05-23 Gaweco Anderson Inibidores de mif e suas utilizações
WO2013066483A1 (en) * 2011-08-31 2013-05-10 Novartis Ag Synergistic combinations of pi3k- and mek-inhibitors
CA2867700A1 (en) * 2012-03-23 2013-09-26 Memorial Sloan-Kettering Cancer Center Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
EP3074016A2 (en) * 2013-11-26 2016-10-05 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders

Also Published As

Publication number Publication date
RU2016133285A (ru) 2018-02-20
JP2017502989A (ja) 2017-01-26
CA2936783A1 (en) 2015-07-23
AU2017245302B2 (en) 2019-04-04
BR112016012141A2 (pt) 2017-08-08
WO2015107461A1 (en) 2015-07-23
KR20160101027A (ko) 2016-08-24
US10085996B2 (en) 2018-10-02
EP3094340A1 (en) 2016-11-23
JP2020023497A (ja) 2020-02-13
US20160331755A1 (en) 2016-11-17
CN112535688A (zh) 2021-03-23
RU2020121929A (ru) 2020-07-13
CN105916515A (zh) 2016-08-31
AU2017245302A1 (en) 2017-11-02
AU2015207723A1 (en) 2016-06-09
RU2016133285A3 (es) 2018-08-28
US20170304311A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
MX2015017629A (es) Combinaciones farmaceuticas.
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
EP4241850A3 (en) Mdm2 inhibitors and combinations thereof
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2019012884A (es) Terapia de combinacion.
WO2015195848A8 (en) Ezh2 inhibitors for treating lymphoma
MX2014002471A (es) Combinaciones sinergicas de los inhibidores de p13k y mek.
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
WO2007058990A3 (en) Therapy using cytokine inhibitors
IN2015DN00376A (es)
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2021001807A (es) Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2015000746A (es) Terapia de combinacion de inhibidores para el receptor del factor de crecimiento insulinico tipo 1 (igf1r) y fosfatidilinositol 3-cinasa (pi3k).
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
WO2015035410A8 (en) Cancer therapy
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2016009226A (es) Combinaciones farmaceuticas.
MX2015017058A (es) Combinaciones farmaceuticas de un inhibidor de pi3k y un agente de desestabilizacion de microtubulos.
MX2016010482A (es) Combinaciones farmaceuticas que comprenden un inhibidor de pi3k para el tratamiento de cancer.
AU2015328044A8 (en) Pharmaceutical composition comprising Aspirin, Metformin, and Serotonin with non-ionic surfactant
RU2010144554A (ru) Средство для предотвращения и/или лечения сосудистых заболеваний
WO2017037578A3 (en) Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer